Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Children with Obesity: An Obesity Medicine Association (OMA) and Expert Joint Perspective 2025

Obesity Pillars, Journal Year: 2025, Volume and Issue: 14, P. 100164 - 100164

Published: Feb. 1, 2025

This Obesity Medicine Association (OMA) Expert Joint Perspective examines steatotic liver disease (SLD), which is composed of metabolic dysfunction-associated (MASLD), and steatohepatitis (MASH) in children with obesity. The prevalence obesity increasing, rates have tripled since 1963 from 5 % to now 19 US affected 2018. MASLD, the most common seen children, can be a precursor development Type 2 Diabetes (T2DM) primary reason for transplant listing young adults. We must vigilant prevention treatment MASLD childhood prevent further progression. joint clinical perspective based upon scientific evidence, peer expertise. medical literature was reviewed via PubMed search appropriate articles were included this review. work formulated collaboration eight hepatologists/gastroenterologists expertise two physicians OMA. authors who are experts field, determined sentinel questions often asked by clinicians regarding They created consensus guideline on screening, diagnosis, associated children. comorbidity increasing problem that needs addressed urgently. It well known chronic continue these diseases as adults, leads reduced life expectancy, quality life, healthcare financial burden. paper recommend healthy weight reduction not only through lifestyle modification but pharmacotherapy bariatric surgery. Therefore, guidance reviews available therapies achieve reverse progressive fibrosis, disease.

Language: Английский

---

Body composition changes during weight reduction with tirzepatide in the SURMOUNT‐1 study of adults with obesity or overweight

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 25, 2025

Abstract Aims We assessed changes in body composition following tirzepatide treatment a substudy of participants with obesity or overweight from the SURMOUNT‐1 trial, overall and post hoc clinically relevant subgroups. Materials Methods Substudy ( n = 160 2539 SURMOUNT‐1) underwent dual‐energy X‐ray absorptiometry (DXA) at baseline Week 72. Body parameters were evaluated by analysis covariance, logistic regression Fisher's exact test. Post subgroup analyses conducted sex (female male), age (<50, 50 to <65, ≥65 years) total weight reduction tertiles (≤15.3 kg, >15.3 ≤25.9 >25.9 kg). Results The (pooled doses 124, placebo 36) end study DXA data 73% female had mean 102.5 kg mass index 38.0 kg/m 2 . change weight, fat lean 72 was −21.3%, −33.9% −10.9% −5.3%, −8.2% −2.6% placebo, respectively p < 0.001 for all comparisons). Of lost, approximately 75% 25% both placebo. These proportions remained consistent across most analyses. Conclusions In significantly reduced compared while analyses, proportion lost as relatively including

Language: Английский

---

Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss

Biomolecules, Journal Year: 2025, Volume and Issue: 15(3), P. 408 - 408

Published: March 13, 2025

Worldwide, nearly 40% of adults are overweight and 13% obese. Health consequences excess weight include cardiovascular diseases, type 2 diabetes, dyslipidemia, increased mortality. Treating obesity is challenging calorie restriction often leads to rebound gain. Treatments such as bariatric surgery create hesitancy among patients due their invasiveness. GLP-1 medications have revolutionized loss can reduce body in obese by between 15% 25% on average after about 1 year. Their mode action mimic the endogenous GLP-1, an intestinal hormone that regulates glucose metabolism satiety. However, drugs carry known risks and, since use for recent, may unforeseen well. They a boxed warning people with personal or family history medullary thyroid carcinoma multiple endocrine neoplasia syndrome 2. Gastrointestinal adverse events (nausea, vomiting, diarrhea) fairly common while pancreatitis obstruction rarer. There be lean mass well premature facial aging. A significant disadvantage using these high rate regain when they discontinued. Achieving success pharmacologic treatment then weaning avoid future negative effects would ideal.

Language: Английский

---

How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis

Obesity Reviews, Journal Year: 2025, Volume and Issue: unknown

Published: April 3, 2025

Summary Glucagon‐like peptide‐1 receptor agonists (GLP1RAs) are used for the management of type 2 diabetes (T2DM) and obesity. GLP1RAs induce significant weight loss but concerns have been raised regarding associated effects on muscle mass (MM). We therefore conducted a systematic review meta‐analysis assessing various measures MM in individuals living with overweight or obesity, without T2DM. Comprehensive search Medline, Pubmed, EMBASE, CINAHL, Cochrane Central Register Controlled Trials (CENTRAL), Google Scholar was performed. Studies involving cohorts mean age over 40 years body index 25 kg.m ‐2 were included. The primary outcome any measure to estimate MM, whilst fat (FM) total included as secondary outcomes. Thirty‐eight publications, 1735 participants, review. Separate meta‐analyses performed studies participants T2DM (non‐DM). In T2DM, induced non‐significant reduction (‐0.74 kg, 95% CI: ‐1.61, 0.14, p = 0.10), despite significantly reducing FM (‐3.18 ‐4.09, ‐2.28, < 0.0001). non‐DM analysis, observed (‐1.41 ‐2.12, ‐0.71, 0.0001), however, this less than (‐6.02 ‐7.53, ‐4.50, both populations, accounted 20% reduction. These findings provide some clarity clinicians that use manage and/or further more detailed analysis impact these medications functional skeletal is required.

Language: Английский

---

Deriving Sex-Specific Anthropometric Cut-Points for Obesity and Cardiovascular Disease Risk in Qatari Adults

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: April 21, 2025

Objective: Obesity, defined using body mass index, is a key risk factor for cardiovascular disease (CVD), diabetes, and dyslipidemia. However, global anthropometric thresholds like those established by the World Health Organization (WHO) may inadequately capture health risks associated with obesity in specific populations. This study aimed to derive population- sex-specific cut-points better predict CVD assess misclassification among Qatari adults. Methods: Using cross-sectional sample of 6,000 participants from Qatar Biobank (QBB), we applied receiver operating characteristic (ROC) curve analyses identify indices that align fat percentage (%BF) disease-specific elevated blood pressure (EBP), Misclassification examined limitations WHO-recommended compared ROC-derived thresholds. Results: The consisted relatively young adults high levels adiposity (BMI: 28.6±5.18 kg/m² males, 29.6±6.27 females; Waist Circumference (WC): 93.2±13.1 cm 84.1±13.4 females). %BF-defined prevalence (87% 91% females) exceeded BMI-based estimates (34% 44% Findings revealed optimal BMI cut points were 25.2 males 24.8 females. Similarly, WC 84.3 74.5 females, also lower than standards. Disease-specific varied, highlighting unique biological pathways underlying EBP, dyslipidemia showed 54.6% 43.0% females misclassified WHO point. Higher rates observed where 87.5% %BF without Conclusion: These results highlighted need population-specific measures improve classification an Arab sample.

Language: Английский

---

GLP-1-based therapies for diabetes, obesity and beyond

Nature Reviews Drug Discovery, Journal Year: 2025, Volume and Issue: unknown

Published: April 25, 2025

Language: Английский

---

Sarcopenic obesity and weight loss-induced muscle mass loss

Current Opinion in Clinical Nutrition & Metabolic Care, Journal Year: 2025, Volume and Issue: unknown

Published: April 23, 2025

Purpose of review Sarcopenic obesity is a clinical condition characterized by the coexistence excess adiposity and impaired muscle function, associated with heightened cardiometabolic risk frailty. The emergence new incretin-based management medications (OMMs), which allow unprecedented weight loss, has raised concerns regarding loss-induced fat-free mass (FFM) reduction, including skeletal (SMM). This examines recent findings on prevalence, diagnosis, implications sarcopenic obesity, explores effects weight-loss interventions body composition their impact health, discusses strategies to preserve mass. Recent Weight loss induced OMMs results in variable but significant reduction FFM. extent this affects SMM function remains uncertain. Nutritional strategies, particularly adequate protein intake, structured exercise interventions, especially resistance training, play key role mitigating FFM loss. Digital health telemedicine-based programs offer promising approaches for maintaining during Summary significance debated. Future research should refine diagnostic criteria, assess long-term FFM/SMM intentional evaluate that optimize while preserving functional health.

Language: Английский

---

Beyond Drive for Thinness: Drive for Leanness in Anorexia Nervosa Prevention and Recovery

Women, Journal Year: 2024, Volume and Issue: 4(4), P. 529 - 540

Published: Dec. 9, 2024

Anorexia nervosa is classified by the American Psychological Association as an eating-related mental disorder, which affects mostly young adult women and adolescent girls. Although refeeding programs are often used to recover bodyweight in patients with anorexia nervosa, treatment failures high, determinants of disorder remain unknown. The present paper uses a nutritional epidemiology perspective examine from patients’ point view. A grounded-theory literature-review method was search review research findings peer-reviewed literature related etiology including recent qualitative interviews patients. Unlike systematic review, grounded theory more appropriate for developing new explain phenomena like cause, recovery, prevention nervosa. Reviewed suggests that may be problematic body-change strategy rather than disorder. Additionally, proposes replacing drive thinness leanness help patient especially when guided easily accessible body-composition estimates. Fat-free mass restoration recovery also facilitated resistance training, improves psychological status body composition. dysfunctional dieting knowledge, skills, experience proper weight management has potential preventive effect against More needed investigate applied effects leanness, assessments, resistance-training programs, weight-management skills associated Furthermore, successful application information this adapted peer role model prevent

Language: Английский

---

Exposure to food proteins: from basic knowledge on the requirements to subgroup specificities

Current Opinion in Clinical Nutrition & Metabolic Care, Journal Year: 2024, Volume and Issue: 28(1), P. 25 - 26

Published: Dec. 11, 2024

aDepartment of Pediatrics, University British Columbia bBC Children's Hospital Research Institute cSchool Population and Public Health, Columbia, Vancouver, Canada dUniversité Paris-Saclay, AgroParisTech, INRAE, UMR PNCA, Paris, France Correspondence to Claire Gaudichon, Professeur de Nutrition Humaine, Directrice l'UMR Physiologie la et du Comportement Alimentaire, Campus Agro 22 place l'Agronomie, 91120 Palaiseau, France. E-mail: [email protected]

Language: Английский

---